Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01178021
Other study ID # BAKMAL0903
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date August 2009
Est. completion date February 2014

Study information

Verified date January 2019
Source University of Oxford
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open label two-arm randomized prospective study of two treatments for P. vivax malaria. Patients meeting study inclusion criteria will be enrolled and allocated either chloroquine alone or chloroquine plus primaquine (0.25mg/kg/day for 14 days). Patients will be followed-up for 1 year, with clinical and laboratory examinations at each visit. Patients with recurrent P. vivax infection will be treated with the same medication as initially randomized unless contraindicated. Recurrences in the two arms will be compared to estimate the risk of and mean duration to relapse, classify the relapse pattern as early or late relapse and to estimate the efficacy and safety of the study drugs.

Polymerase Chain Reaction (PCR) analysis will be used as far as possible help to distinguish between relapse and re-infection. Samples for chloroquine pharmacokinetic analysis will be collected on day 7 from each study subject as well as on the day of recurrence if within 8 weeks of chloroquine


Description:

Globally more than 100 countries are endemic of malaria and about 60% of world population are at risk of getting the infection while around 10% are harboring malaria parasite in their blood stream. Of the four species of plasmodium that infect humans, Plasmodium vivax is responsible for 50% of all malaria cases outside Africa, and is endemic in the Middle East, Asia and Western Pacific, with a lower prevalence in Central and South America a common cause of malaria in many tropical and subtropical regions. Conventional control methods are rather inefficient for preventing transmission of this species of malaria. This is partly due to the persistence of the infectious reservoir, which take the form of latent hypnozoites in the liver, producing recurrent relapses and opportunities for new transmission for several years after initial infection.

Primaquine (PQ) is the only available drug regimen which can eliminate the persisting liver stages (hypnozoites) of P. vivax,but its use for 14 days is ineffective to prevent relapses at 15 mg daily dose (0.25mg/kg) in Southeast Asia and in Brazil, and at a higher dose of 22.5 mg daily in the Southwest Pacific. Due to high relapse rates, a primaquine regimen of 30 mg daily (0.5 mg/kg) for 14 d is now widely recommended for glucose-6-phosphate dehydrogenase (G6PD) normal patients.

P.vivax is the predominant species in Pakistan and eastern Afghanistan. In this area G6PD deficiency is a common trait (7% in Pakistani and 14% in Afghan Pashtoon respectively). However facilities to test for G6PD deficiency are not available and hence routine administration of primaquine is not recommended in national guidelines because of the risk of severe haemolysis in those who cannot be tested.

Several national malaria programmes in Asia have adopted a truncated 5-day course of PQ for vivax malaria to reduce the risk of haemolysis to reasonable levels and to increases compliance rates. Recently this has been documented as being ineffective at reducing relapse rates amongst Afghan refugees in Pakistan while a supervised 14 day course can significantly reduce the frequency of second and third episodes of disease. This is also confirmed by a study in India. Use of the 14 day course is only recommended where the G6PD status of the individual is known, and, currently, where compliance with the full course can be assured. However supervision of patients for 14 day post presentation is seldom feasible in the majority of settings where vivax malaria predominates. Therefore the supposition that patients in a low literacy population will not comply with a 14 day course of treatment in the absence of supervision needs to be confirmed under normal operational conditions. Compliance in taking the drug cannot be monitored by direct observation or by chemical assay of residues in the blood because such interference may, in itself, affect compliance.


Recruitment information / eligibility

Status Completed
Enrollment 593
Est. completion date February 2014
Est. primary completion date February 2014
Accepts healthy volunteers No
Gender All
Age group 6 Months and older
Eligibility Inclusion Criteria:

- Adults and children >6 months

- Negative pregnancy test in women at risk of pregnancy

- Microscopic diagnosis of Plasmodium vivax mono-infection (>200/µl asexual forms)

- Axillary temperature =37.5°C or oral/rectal temperature =38°C or history of fever within the last 24 hours

- Ability to swallow oral medication

- Participant (or parent/guardian if <18 years old) is willing and able to give written informed consent

- Ability (in the investigator's opinion) and willingness of patient or parent/guardian to comply with all study requirements

Exclusion Criteria:

- Severe malaria (see WHO definition)

- Patients with microscopic diagnosis of co-infection with Plasmodium falciparum

- Haemoglobin concentration <8g/dl

- Presence of any condition which in the judgement of the investigator would place the subject at undue risk or interfere with the results of the study e.g. other acute febrile conditions or chronic disease

- Pregnancy or lactation

- History or phenotypic test compatible with severe G6PD deficiency

- History of hypersensitivity to any of the drugs being tested

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Chloroquine
Chloroquine 10 mg/kg on day 0 & 1 and 5mg/kg on day 2
Chloroquine/Primaquine
Chloroquine 10 mg/kg on day 0 & 1 and 5mg/kg on day 2 Primaquine (if given) 0.25mg/kg/day for 14 days

Locations

Country Name City State
Afghanistan Provincial Malaria Control Centers (MRC) Jalalabad
Afghanistan Provincial Malaria Control Centers (MRC) Kunduz
Afghanistan Provincial Malaria Control Centers (MRC) Maimana Faryab

Sponsors (3)

Lead Sponsor Collaborator
University of Oxford Mahidol University, National Malaria and Leishmaniasis Control Program, Afghanistan

Country where clinical trial is conducted

Afghanistan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Secondary vivax attack Completion of the 1-year (± 1 month) follow-up period without secondary vivax attack 1 year
Secondary secondary vivax attack Completion of 6-months (± 1 month) follow-up without secondary vivax attack 6 months
Secondary G6PD prevalence G6PD status of patients Time of enrollment
Secondary Recurrence Time to first recurrence, median time between episodes of vivax infections and total number of episodes in the follow up period 1 year
Secondary Days of illness, haematocrit Overall number of days of illness and haematocrit below 30% 1 year
Secondary Chloroquine levels Whole blood chloroquine level at day 7 and any day of recurrence of Plasmodium vivax malaria Day 7
Secondary Adverse events Adverse event profiles of chloroquine and primaquine 1 year
See also
  Status Clinical Trial Phase
Completed NCT01625871 - Artemether/Lumefantrine and Vivax Malaria Phase 3
Completed NCT02876549 - G6PD Assessment Before Primaquine for Radical Treatment of Vivax Malaria Phase 4
Completed NCT01218932 - Pharmacokinetic Study of Primaquine and Chloroquine in Healthy Subjects Phase 1
Recruiting NCT04228315 - Biomarkers of P. Vivax Relapse N/A
Completed NCT02118090 - Assessment of Plasmodium Vivax Chloroquine Resistance in Cambodia: Phase 4
Completed NCT01074905 - Study on the Treatment of Vivax Malaria Phase 3
Completed NCT04222088 - TES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014
Completed NCT01546961 - Chloroquine Population Pharmacokinetics in Pre and Post-partum Women N/A
Completed NCT00158548 - ACT With Chloroquine, Amodiaquine & Sulphadoxine-pyrimethamine in Pakistan Phase 3
Completed NCT00682578 - A Comparative Study of Artekin With Standard Malarial Treatment Regimes in Afghanistan Phase 3
Completed NCT00157833 - A Randomized Trial of Coartemether and Artekin for the Treatment of Uncomplicated Malaria in Papua, Indonesia. N/A
Active, not recruiting NCT03529396 - Safety and Efficacy of Different Regimens of Primaquine on Vivax Malaria Treatment in G6PD Deficient Patients Phase 2
Recruiting NCT05874271 - Short Course Primaquine for the Radical Cure of P. Vivax - Papua New Guinea N/A
Completed NCT05958797 - TES of Chloroquine for Pv in the Philippines in 2016
Completed NCT01716260 - Safety and Efficacy of Chloroquine and Primaquine for Vivax Malaria in Bhutan N/A
Completed NCT01288820 - Study of ACTs Plus Primaquine for Uncomplicated Plasmodium Vivax Malaria Phase 3
Completed NCT01640574 - Comparison Between 7 and 14 Day Primaquine Combined With Dihydroartemisinin-piperaquine or 3 Day Chloroquine Radical Cure of P. Vivax (BPD) Phase 3
Completed NCT01076868 - Incidence of Vivax Along the Thai Burma Border N/A
Completed NCT00158561 - Chlorproguanil/Dapsone Compared With Chloroquine and SP for Vivax Malaria Phase 3
Completed NCT01780753 - Primaquine Pharmacokinetics in Lactating Women and Their Infants Phase 1